Biological descriptionPotent, selective D2-likedopamine receptor agonist (Ki values are ~8 (D2), ~5 (D3), ~290 (D4), ~440 (D1) and ~450 nM (D5)). Inhibits the release of pituitary prolactin and stimulates motor activity in Parkinson's disease. Also reverses glutamate transporter 1 (GLT-1) activity, increasing glutamate levels.
Chemical name(5α)-2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione methanesulfonate
Storage instructionsStore at +4°C. The product can be stored for up to 12 months.
Solubility overviewSoluble in DMSO to 100 mM and in ethanol to 25 mM (with heating)
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Shirasaki Y et al. Bromocriptine, an ergot alkaloid, inhibits excitatory amino acid release mediated by glutamate transporter reversal. Eur J Pharmacol643:48-57 (2010).
Read more (PubMed: 20599932) »
Lindgren HS et al. Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease. Neuropsychopharmacology34:2477-88 (2009).
Read more (PubMed: 19606087) »
Valente D et al. Metabolite involvement in bromocriptine-induced prolactin inhibition in rats. J Pharmacol Exp Ther282:1418-24 (1997).
Read more (PubMed: 9316855) »